Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

SU11274

🥰Excellent
Catalog No. T6154Cas No. 658084-23-2
Alias PKI-SU11274, Met Kinase Inhibitor

SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.

SU11274

SU11274

🥰Excellent
Purity: 99.53%
Catalog No. T6154Alias PKI-SU11274, Met Kinase InhibitorCas No. 658084-23-2
SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$39In StockIn Stock
2 mg$54In StockIn Stock
5 mg$98In StockIn Stock
10 mg$153In StockIn Stock
25 mg$297In StockIn Stock
50 mg$490In StockIn Stock
100 mg$725In StockIn Stock
1 mL x 10 mM (in DMSO)$153In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.53%
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
Targets&IC50
MET:0.01 μM
In vivo
SU11274 inhibits the phosphorylation of key regulators in the PI3K pathway, including AKT, FKHR, and GSK3β. It also inhibits the HGF-dependent phosphorylation of Met and the subsequent HGF-dependent cellular proliferation and activity, with an IC50 ranging from 1 to 1.5 μM. In BaF3 cells transformed by TPR-MET, the presence of interleukin-3 and treatment with SU11274 suppress cell growth in a dose-dependent manner. However, SU11274 (IC50 <3 μM) does not inhibit the growth of BaF3 cells transformed by other oncogenic tyrosine kinases, including BCR-ABL, TEL-JAK2, TEL-ABL, and TEL-PDGFβR. Treatment with SU11274 also significantly inhibits cell migration in BaF3.TPR-MET cells with inhibitions of 44.8% and 80% at concentrations of 1 μM and 5 μM, respectively. In H69 and H345 cells, which possess functional Met receptors, SU11274 inhibits HGF-induced cell growth with IC50 values of 3.4 μM and 6.5 μM, respectively. In non-small cell lung cancer (NSCLC) cells expressing c-Met, SU11274 inhibits cell viability with an IC50 of 0.8-4.4 μM and abrogates the phosphorylation of c-Met and its downstream signaling induced by hepatocyte growth factor.
Kinase Assay
In vitro Met kinase assay: A chimeric protein is constructed containing the cytoplasmic domain of human c-Met fused to Glutathione S-transferase (GST) and expressed in SF9 cells. The c-Met kinase GST-fusion protein is used for an ELISA-based Met biochemical assay using the random copolymer poly(Glu:Tyr) (4:1) immobilized on microtiter plates as a substrate. IC50 value is determined with various concentrations of SU11274 in a buffer containing 5 μM ATP and 10 mM MnCl2, 50 mM HEPES (pH 7.5), 25 mM NaCl, 0.01% BSA, and 0.1 mM Na orthovanadate. The kinase reaction is performed for 5 minutes at room temperature. The extent of substrate phosphorylation is measured using horseradish peroxidase-conjugated anti-pTyr antibodies.
Cell Research
Cells are exposed to various concentrations of SU11274 in the presence or absence of HGF for 24, 48, and 72 hours. The number of viable cells is determined using the MTT assay or trypan blue exclusion. Cell Cycle and apoptosis are measured by fluorescence-activated cell sorter analysis via propidium iodide staining and Annexin V-positive staining, respectively. (Only for Reference)
SynonymsPKI-SU11274, Met Kinase Inhibitor
Chemical Properties
Molecular Weight568.09
FormulaC28H30ClN5O4S
Cas No.658084-23-2
SmilesC(=C\1/C=2C(NC1=O)=CC=C(S(N(C)C3=CC(Cl)=CC=C3)(=O)=O)C2)\C4=C(C)C(C(=O)N5CCN(C)CC5)=C(C)N4
Relative Density.1.401g/cm3
Storage & Solubility Information
StorageIn solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 2 mg/mL (3.52 mM), Sonication is recommended.
DMSO: 48.33 mg/mL (85.07 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.81 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
Ethanol/DMSO
1mg5mg10mg50mg
1 mM1.7603 mL8.8014 mL17.6028 mL88.0142 mL
DMSO
1mg5mg10mg50mg
5 mM0.3521 mL1.7603 mL3.5206 mL17.6028 mL
10 mM0.1760 mL0.8801 mL1.7603 mL8.8014 mL
20 mM0.0880 mL0.4401 mL0.8801 mL4.4007 mL
50 mM0.0352 mL0.1760 mL0.3521 mL1.7603 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy SU11274 | purchase SU11274 | SU11274 cost | order SU11274 | SU11274 chemical structure | SU11274 in vivo | SU11274 formula | SU11274 molecular weight